Digoxin and its related endogenous factors

Critical Reviews in Clinical Laboratory Sciences

Volumn 34, Issue 3, 1997, Pages 225-274

  Jortani, Saeed A ^a   Valdes Jr , Roland ^a,b  

^a Depts of Pathology and Biochemistry   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Cross reactivity; Digibind ; Digitalis; Digoxin; Digoxin immunoassays; Isoforms; Ouabain; Sodium pump

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BUFALIN; DIGITALIS; DIGITALIS LIKE FACTOR; DIGITOXIN; DIGOXIGENIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; DRUG METABOLITE; DRUG RECEPTOR; OUABAIN;

AUTONOMIC NEUROPATHY; BIOTRANSFORMATION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CROSS REACTION; DIGOXIN BLOOD LEVEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKELETAL MUSCLE;

DIGITALIS; MAMMALIA; STROPHANTHUS GRATUS;

EID: 0030739984     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369708998094     Document Type: Review

References (195)

1. Akera T. Membrane adenosinetriphosphatase: a digitalis receptor? Science 1977; 198: 569-74.
2. Shull GE, Schwartz A Lingrel JB. Amino acid sequence of the catalytic subunit of the (Na,K) ATPase deduced from a complementary DNA. Nature (London) 1985; 316: 691-5.
3. Shull GE, Greeb J Lingrel JB. Molecular cloning of three distinct forms of the Na,K-ATPase α-subunit from rat brain. Biochemistry 1986; 25: 8125-32.
4. Grishin AV, Sverdlov VE, Kostina MB, et al. Cloning and characterization of the entire cDNA encoded by ATP1AL1 - a member of the human Na,K/A,K-ATPase gene family. FASEB Lett 1994; 349: 144-50.
5. Gruber KA, Whitaker JM Buckalew VM Jr. Endogenous digitalis-like substances in plasma of volume expanded dogs. Nature (London) 1980; 287: 743-749.
6. Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985; 31: 1526-1532.
7. Hamlyn JM, Blaustei MP. Endogenous digitalis-like compounds: putative regulators of the sodium pump. TINS 1984; September: 307-8.
8. Clerico A, Balzan S, Del Chicca MG, et al. Endogenous cardiac glycoside-like substances in newborns, adults, pregnant women and patients with hypertension or renal insufficiency. Drugs Exp Clin Res 1988; 14: 603-607.
9. Doris PA. Regulation of Na,K-ATPase by endogenous ouabain-like material. PSEBM 1994; 205: 202-212.
10. Woolfson RG, Poston L De Wardener HE. Digoxin-like inhibitors of active sodium transport and blood pressure: the current status. Kidney Int 1994; 46: 297-309.
11. Sweadner KJ. Overview: subunit diversity in the Na,K-ATPase. In: Kaplan JH, DeWeer P, eds. The sodium pump: structure, mechanism, and regulation. Pp. 63-76. New York: Rockefeller University Press, 1991.
12. Rose AM, Valdes R Jr. Understanding the sodium pump and its relevance to disease. Clin Chem 1994; 40: 1674-1685.
13. Thompson JN. Ouabain: a new steroid hormone? Lancet 1995; 346: 1381-1382.
14. Weiler EWJ, Saldanha LF Kalil-Manesh F. Relationship of Na-K-ATPase inhibitors to blood-pressure regulation in continuous ambulatory peritoneal dialysis and hemodialysis. J Am Soc Nephrol 1996; 7: 454-463.
15. Smith TW, Haber E. Digitalis (first of four parts). N Engl J Med 1973; 289: 945-951.
16. Hoffman BF, Bigger T Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's pharmacological basis of therapeutics, 8th ed. Pp. 814-39. New York: McMillan, 1990.
17. Greeff K, Schadewaldt H. Introduction and remarks on the history of cardiac glycosides. In Greeff K, ed. Cardiac glycosides, part II (pharmacokinetics and clinical pharmacology). Pp. 1-12. New York: Springer-Verlag, 1981.
18. Brown BT, Stafford A Wright SE. Chemical structure and pharmacological activity of some derivatives of digitoxigenin and digoxigenin. B J Pharmacol 1962; 18: 311-324.
19. Withering W. An account of the foxglove, and some of its medical uses: with practical remarks on dropsy and other diseases. Bermingham, 1785.
20. MacGregor SE, Walker JM. Inhibitors of Na+, K+-ATPase. Comp Biochem Physiol 1993; 105C: 1-9.
21. Physician Drug and Diagnosis Audit (personal inquiry for 1994 and 1995 data). Scott-Levin Associates, a subsidiary of Pharmaceutical Marketing Services, Inc. Newtown, PA, 1996.
22. Lanoxin tablets. In: Physicians' Desk Reference, 49th ed. Pp. 765-780. Montvale: Medical Economics Company, Inc., 1995.
23. Grosse-Brockhoff F, Peters U. Clinical indications and choice of cardiac glycosides, clinical conditions influencing glycoside effects. In: Greeff K, ed. Cardiac glycosides, part II (pharmacokinetics and clinical pharmacology). Pp. 239-75. New York: Springer-Verlag, 1981.
24. Am Drug 1995; February: 21-22.
25. Indolfi C, Piscione F, Russolillo E, et al. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am J Cardiol 1991; 68: 1274-1278.
26. American Hospital Formulary Service. Cardiac drugs. Pp. 586-596. 1985.
27. Di Bianco R. The changing syndrome of heart failure: an annotated review as we approach the 21st century. J Hypertens 1994; 12: S73-S87.
28. Smith JR, Gheorghiade M, Goldstein S. The current role of digoxin in the treatment of heart failure. Coronary Artery Dis 1993; 4: 16-26.
29. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative group. J Am Coll Cardiol 1993; 22: 955-962.
30. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329: 1-7.
31. Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing maintanence dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure with diuratic and angiotensin-converting enzyme inhibitors. Circulation 1995; 92: 1801-7.
32. Leor J, Goldbourt U, Behar S, et al. Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy. Am Heart J 1995; 130: 1322-1326.
33. Wilson PAP. Digoxin-doubts to dampen enthusiasm. Cardiovasc Drug Ther 1993; 7: 897-898.
34. Leor J, Goldbourt U, Behar S, et al. Digoxin and mortality in survivors of acute myocardial infarction: observation in patients at low and intermediate risk. Cardiovasc Drug Ther 1995; 9: 609-617.
35. Casella G, Cantelli I, Pavesi PC, et al. Comparative hemodynamic effects of intravenous digoxin and enoximone in severe chronic heart failure. Cardiology 1994; 85: 303-310.
36. Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clin Trials 1996; 17: 77-97.
37. Ferguson JJ. Meeting highlights. American College of Cardiology 45th Annual Scientific Session. Circulation 1996; 94: 1-5.
38. Benthe HF. Effects of cardiac glycosides on the central nervous system. In: Greef K, ed. Cardiac glycosides, Part I (experimental pharmacology). Pp. 489-96. New York: Springer-Verlag, 1981.
39. Krum H, Bigger T, Goldsmith RL, et al. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25: 289-94.
40. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-71.
41. 3H-oubaine binding sites in biopsies of human skeletal muscles. Scand J Clin Lab Invest 1984; 44: 509-518.
42. + pump in skeletal muscle: quantitation, regulation and functional significance. Acta Physiol Scand 1996; 156: 227-235.
43. Denes B, Greeff K. Effects of cardiac glycosides on skeletal muscle. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 517-32. New York: Springer-Verlag, 1981.
44. Joreteg T. Binding of digoxin to slow- and fast-twitch skeletal muscle fibers. Clin Physiol 1986; 6: 357-363.
45. Joubert PH. Effects of cardiac glycosides on the autonomic nervous system and endocrine glands. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 533-45. New York: Springer-Verlag, 1981.
46. Dock W, Tainter ML. The circulatory changes after full therapeutic doses of digitalis, with a critical discussion on views on cardiac output. J Clin Invest 1930; 8: 467-475.
47. Mason DT. Effects of cardiac glycosides on vascular system. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 497-515. New York: Springer-Verlag, 1981.
48. Horwitz LD, Atkins JM Saito M. Effects of digitalis on left ventricular function in exercising dogs. Circ Res 1977; 41: 744-749.
49. Mason DT. Afterload reduction and cardiac performance. Am J Med 1978; 65: 520-530.
50. Phillips CDF, Bradford JR. On the action of certain drugs on the circulation and secretion of the kidney. J Physiol 1876; 8: 117.
51. Hyman AL, Jaques WE Hyman ES. Observation on the direct effect of digoxin on renal excretion of sodium and water. Am Heart J 1956; 52: 592-608.
52. Cade JR, Shalhoub RJ, Canessa-Fischer M, et al. Effect of strophanthidin on the renal tubules of dogs. Am J Physiol 1961; 200: 373-379.
53. Heidenreich O, Osswald H. Effects of cardiac glycosides on the kidneys. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 533-45. New York: Springer-Verlag, 1981.
54. McDonough AA, Hensley CB Azuma KK. Differential regulation of sodium pump isoforms in heart. Semin Nephrol 1992; 12: 49-55.
55. Skou JC. The influence of some cations on an adenosine triphosphate from peripheral nerves. Biochem Biophys Acta 1957; 23: 394-401.
56. +-pump by cardiac glycosides. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 381-406. New York: Springer-Verlag, 1981.
57. +)-ATPase: implications for the mechanism of ouabain action. Prog Clin Biol Res 1988; 268A: 211-8.
58. Calhoun JA, Harrison TR. Studies in congestive heart failure. IX. The effect of digitalis on potassium content of cardiac muscle of dogs. J Clin Invest 1931; 10: 139-144.
59. 45calcium uptake in frog's heart. Fed Am Soc Exp Biol 1958; 17: 162.
60. Weingart R, Kass RS Tsien RW. Is digitalis inotropy associated with enhanced slow inward calcium current? Nature (London) 1978; 273: 389-392.
61. Beeler GW. Ionic currents in ardiac muscles; a framework for glycoside action. Fed Proc 1977; 36: 2209-2213.
62. 2+ by cardiotonic drugs. In: Xoshida H, Hagiwara Y, Ebash S, eds. Advances in pharmacology and therapeutics II. Volume 3. Cardio-renal and cell pharmacology. Pp. 205-16. Oxford: Pergamon Press, 1982.
63. Eisner DA, Lederer WJ. Na-Ca exchange: stoichemistry and electrogenicity. Am J. Physiol 1985; 248: C189-C202.
64. Godfraind T, Ghysel-Burton J. Binding sites related to ouabain-induced stimulation or inhibition of the sodium pump. Nature (London) 1977; 265: 165-6.
65. Okarma TB, Tramell P Kalman SM. The surface interaction between digoxin and cultured heart cells. J Pharmacol Exp Ther 1972; 183: 559-76.
66. Lingrel JB, Orlowski J, Shull MM, et al. Molecular genetics of Na,K-ATPase. Prog Nucleic Acid Res Mol Biol 1990; 38: 37-89.
67. + activity of "diseased" human atrial muscles and its modification by dihydro-ouabain. Jpn J Phys 1993; 43: 403-8.
68. Pw L, Cs H Swaminathan R. The chronic effects of long-term digoxin administration on Na+/K(+)-ATPase activity in rat tissues. Int J Cardiol 1993; 40: 95-100.
69. McGarry SJ, Williams AJ. Digoxin activates sarcoplasmic reticulum Ca2+-release channels: a possible role in cardiac inotropy. Br J Pharmacol 1993; 108: 1043-50.
70. Fujino M, Fujino S. An immunohistochemical study of the significance of a new 31.5-kDa ouabain receptor protein isolated isolated from cat cardiac muscle. Jpn J Pharmacol 1995; 67: 125-135.
71. Miller JJ, Suarez CP, Valdes R Jr. Preliminary characterization of DLIF-binding protein from human serum. Clin Chem 1990; 36: 1156.
72. Rahmani-Jourdhheuil D, Masset D, Coppens R, et al. Intestinal absorption of drugs: digitalis binding and transport by brush-border membrane vesicles from human duodenum. Eur J Drug Metab Pharmacokinet 1991; S3: 447-55.
73. Watson ADJ, Church DB, Emsile DR, et al. Effect of injesta and of tablets of different strengths on the systemic availability of digoxin in normal dogs. Res Vet Sci 1995; 58: 203-5.
74. Durakovic Z. Does any correlation exist between a high plasma digoxin level and electrocardiogram in older and younger patients? Ind Heart J 1993; 45: 37-40.
75. Hui J, Geraets DR, Chandrasekaran A, et al. Digoxin disposition in elderly humans with hypochlorhydria. J Clin Pharmacol 1994; 34: 734-741.
76. Edner M, Jogestrand T Dahlqvist R. Effect of salbutamol on digoxin pharmacokinetics. Eur J Clin Pharmacol 1992; 42: 197-201.
77. Hedman A, Angelin B, Arvidsson A, et al. Digoxin-interaction in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 1992; 42: 481-485.
78. Pederson KE, Christiansen DB Kligaard NA. Effects of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983; 24: 41-7.
79. Digoxin. In: Windholz M, ed. Merk index, 10th ed. P. 3148. Rahway, NJ: Merk & Co., 1983.
80. Reuning RH, Sams RA Notari R. Role of pharmacokinetics in drug dosage adjustments, I. Pharmacologic effects and apparent volume of distribution of digoxin. J Clin Pharmacol 1973; 13: 127-41.
81. Kuhlmann J, Rietbrock N Schnieders B. Tissue distribution of digoxin and methyldigoxin after single dose and multiple doses in dogs. J Cardiovasc Pharmacol 1979; 1: 219-34.
82. Rietbrock N, Woodcock BG. Pharmacokinetics of digoxin and derivatives. In: Greef K, ed. Cardiac glycosides, part I (experimental pharmacology). Pp. 32-56. New York: Springer-Verlag, 1981.
83. Allonen H, Anderson KE, Iisalo E, et al. Passage of digoxin into cerebralspinal fluid in man. Acta Pharmacol Toxicol 1977; 41: 193-201.
84. Valdes R Jr, Miller JJ. Increasing the specificity of immunoassays. J Clin Immunoassay 1992; 15: 87-96.
85. Kaplanski J, Hovevey-sion D Chayoth R. Effect of acute and chronic exposure to heat on pharmacokinetic parameters of digoxin in rats. Res Commun Chem Pathol Pharmacol 1985; 49: 85-93.
86. Gault HM, Longerich LL, Loo JCK, et al. Digoxin biotransformation. Clin Pharmacol Ther 1984; 35: 74-81.
87. Gault MH, Longrich L, Dawe M, et al. Combined liquid chromatography/ radioimmunoassay with improved specificity for serum digoxin. Clin Chem 1985; 31: 1272-7.
88. Gault MH, Charles JD, Sugden DI, et al. Hydrolysis of digoxin by acid. J Pharm Pharmacol 1980; 29: 27-32.
89. Gault MH, Karla J, Ahmed M, et al. Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis. Clin Pharmacol Ther 1980; 27: 16-21.
90. Gault HM, Karla J, Longerich L, et al. Digoxigenin biotransformation. Clin Pharmacol Ther 1982; 31: 695-704.
91. Lacarelle B, Rahmani R, de Sousa G, et al. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991; 5: 567-82.
92. Jortani SA, Helm RA Valdes R Jr. Two cases in which polar digoxin metabolites explain discrepancy in digoxin immunoassay results. Clin Chem 1996; 42(Abstr): S212.
93. Jortani SA, Straub RW, Qazzaz HMAM, et al. Generation of digoxin-like immunoreactive factors from metabolism of dihydrodigoxin by bovine adrenal cortex microsomes. Clin Chem 1995; 41(Abstr): S45.
94. Qazzaz HMAM, Jortani SA, Poole JM, et al. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (Dihydro-DLIF) in mammalian tissues. Clin Chem 1996; 42: 1092-9.
95. Lindenbaum J, Rund DG, Butler VP, et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789-94.
96. Luchi RJ, Gruber JW. Unusually large digitalis requirements. Am J Med 1968; 45: 322-328.
97. Robertson LW, Chandrasekaran A, Runing RH, et al. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol 1986; 51: 1300-3.
98. Reuning RH, Shepard TA Morrison BE. Formation of {20R}-dihydrodigoxin from digoxin in humans. Drug Metab Dispos 1985; 13: 51-7.
99. Delfert DM, Valdes R Jr. Impact of digoxin-like immunoreactive factors on digoxin measurements by immunoassays. J Clin Immunoassays 1985; 8: 157-64.
100. Craver JL, Valdes R Jr. Anomalous serum digoxin concentration in uremia. Ann Intern Med 1983; 98: 483-4.
101. Gault H, Vasdev S, Vlasses P, et al. Interpretation of serum digoxin values in renal failure. Clin Pharmacol Ther 1986; 39: 530-6.
102. Ibanez C, Carcas AJ Abad FF. Activated charcoal increases digoxin elimination in patients. Int J Cardiol 1995; 48: 27-30.
103. Hedman A. Inhibition of basic drugs of digoxin secretion into human bile. Eur J Clin Pharmacol 1992; 42: 457-9.
104. Digibind. In: Physicians' Desk Reference, 49th ed. Pp. 755-7. Montvale: Medical Economics, 1995.
105. Smith TW, Butler VP Haber E. Determination of therapeutic and toxic digoxin concentrations by radioimmunoassay. N Engl J Med 1969; 281: 1212-6.
106. Shapiro W, Taulbert K Naraharnk K. Nonradioactive serum digoxin and digitoxin levels. Arch Intern Med 1972; 130: 13-36.
107. Ingelfinger JA, Goldman P. The serum digoxin concentration - does it diagnose digoxin toxicity? N Engl J Med 1976; 294: 867-70.
108. Howanitz PJ, Steindel SJ. Digoxin therapeutic monitoring practices, a College of American Pathologists Q-Probes study of 666 institutions and 18679 toxic levels. Arch Pathol Lab Med 1993; 117: 684-90.
109. Bernard DW, Bowman RL, Grimm FA, et al. Nighttime dosing assures postdistribution sampling for therapeutic monitoring of digoxin. Clin Chem 1996; 42: 45-9.
110. Lowenstein JM. A method for measuring plasma level of digitalis glycosides. Circulation 1965; 31: 228-33.
111. Lowenstein JM, Corrill EM. An improved method for measuring plasma and tissue digitalis glycosides. J Lab Clin Med 1966; 67: 1048-52.
112. 3H-ouabain from Na-K ATPase. Circulation 1972; 45: 20-36.
113. +-ATPase inhibitors. Clin Biochem 1992; 25: 15-9.
114. Miller JJ, Straub RW, Valdes R Jr. Digoxin immunoassay with cross-reactivity of digoxin metabolites proportional to their biological activity. Clin Chem 1994; 40: 1898-1903.
115. Soldin SJ. Digoxin - issues and controversies. Clin Chem 1986; 32: 5-12.
116. Soldin SJ, Rifai N, Palaszynski EW, et al. Development of radioreceptor assay to measure glucocorticoids. Ther Drug Monit 1992; 14: 164-8.
117. Houk AEH, Alexander TG Banes D. The analysis of digoxin preparations. J Am Pharm Assoc 1959; 48: 217.
118. Penelope R, Foss B Benezra SA. Digoxin. In: Florey K, ed. Analytical profiles of drug substances, Vol 9. Pp. 217-42. New York: Academic Press, 1980.
119. Bockbrader HN, Reuning RH. Digoxin and metabolites in urine: a derivatization-high-performance liquid chromatographic method capable of quantitating individual epimers of dihydrodigoxin. J Chromatog 1984; 310: 85-95.
120. Shepard TA, Hui J Chandrasekaran A. Digoxin and metabolites in urine and feces: a fluorescence derivatization-high-performance liquid chromatographic technique. J Chromatog 1986; 380: 89-98.
121. Eichhorst O, Hinderling PH. Specific assay for radiolabelled digoxin and its known apolar metabolites in biological fluids. J Chromatogr 1981; 224: 67-93.
122. Szeleczky Z, Soti M, Horvath G, et al. 7b-Hydroxycardenolide glycosides. Steroids 1981; 38: 11-27.
123. Greenwood H, Snedden W, Hayward RP, et al. The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectrscopy. Clin Chim 1975; 62: 213-24.
124. Stone JA, Soldin SJ. Improved liquid chromatographic/immunoassay of digoxin in serum. 1988; 34: 2547-51.
125. Jortani SA, Miller JM Valdes R Jr. Resolving discrepant digoxin results: a case involving multiple interferants. J Clin Ligand Assay 1996; 19: 131-7.
126. Liu X, Xu Y Ip MPC. Capillary electrophoeretic enzyme immunoassay for digoxin in human serum. Anal Chem 1995; 67: 3211-8.
127. Kaneki N, Xu Y Kumari A, et al. Electrochemical enzyme immunoassay using saturation technique in a 20-μl capillary: digoxin as a model analyte. Anal Chem Acta 1994; 287: 253-8.
128. Valdes R Jr, Miller JJ. Importance of using molar concentrations to express cross-reactivity in immunoassays (Lett). Clin Chem 1995; 41: 332-3.
129. Skou JC. Overview: the Na,K-pump. Methods Enzymol 1988; 156: 1-24.
130. Feldman H, Rodbard D Levine D. Mathematical theory of crossreactive radioimmunoassay and ligand-binding systems at equilibrium. Anal Biochem 1972; 45: 530-56.
131. Pratt JJ. Steroid immunoassay in clinical chemistry. Clin Chem 1978; 24: 1869-90.
132. Miller JJ, Hess PP Valdes R Jr. The effect of digoxin on digoxin-like immunoreactive factor (DLIF) interference varies among digoxin assays. J Clin Immunoassay 1992; 15 (Abstr): 63.
133. Lau BWC, Valdes R Jr. Criteria for identifying endogenous compounds as digoxin-like immunoreactive factors in humans. Clin Chem Acta 1988; 175: 67-78.
134. Valdes R Jr, Graves SW, Brown BA, et al. Endogenous substance in newborn infants causing false positive digoxin measurements. J Pediatr 1983; 102: 947-50.
135. Seccombe DW, Pudek MR. Whitfield MF, et al. Perinatal changes in a digoxin-like immunoreactive substance. Pediatr Res 1984; 18: 1097-9.
136. Graves SW, Valdes R Jr, Brown BA, et al. Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Metab 1984; 58: 748-51.
137. Lucena MI, Andrade RJ Fraile JM. Endogenous digoxin-like substances in liver failure. Int J Clin Pharmacol Ther 1994; 32: 567-9.
138. Frisolone J, Sylvia LM, Gelwan J, et al. False-positive digoxin cocentrations determined by three digoxin assays in patients with liver disease. Clin Pharm 1988; 7: 444-9.
139. Valdes R Jr, Hagberg JM, Vaughan TE, et al. Endogenous digoxin-like immunoreactivity in blood is increased during prolonged strenuous exercise. Life Sci 1988; 42: 103-10.
140. Bagrov AY, Kuznetsova EA Fedorova OV. Endogenous digoxin-like factor in acute myocardial infarction. J Int Med 1994; 235: 63-7.
141. Tamura H, Shimoyama S, Sunaga Y, et al. Digoxin-like immunoreactive substance in urine of patients with mucocutaneous lymph node syndrome (MCLS). J Vasc Dis 1992; 43: 856-65.
142. Berendes E, Walter M, Prien T, et al. Digoxinlike immunoreactive substance in critically ill patients. Anesthesiology 1994; 80: 1408-9.
143. Bednarczyk B, Soldin SJ, Gasinka I, et al. Improved receptor assay for measuring digoxin activity. Clin Chem 1988; 34: 393-7.
144. Qazzaz HMAM, Goudy S, Miller JJ, et al. Treatment of human serum with sulfosalicylic acid structurally alters digoxin and endogenous digoxin-like immunoreactive factor. Ther Drug Monit 1995; 17: 53-9.
145. Qazzaz HMAM, Goudy S Valdes R Jr. Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue. J Biol Chem 1996; 15: 8731-7.
146. Metheke ML, Valdes R Jr. A physician's office-based digoxin assay (seralyzer) evaluated for interference by endogenous digoxin-like immunoreactive factors. Ann Clin Lab Sci 1989; 19: 168-74.
147. Jortani SA, Miller JJ, Helm RA, et al. Unexpected suppression of digoxin values caused by DLIF. Clin Chem 1996; 42 (Abstr): S124.
148. Fushimi R, Koh T, Iyama S, et al. Digoxin-like immunoreactivity in Chinese medicine. Ther Drug Monit 1990; 12: 242-5.
149. Osterloh J, Herold S Pond S. Oleander interference in the digoxin radioimmunoassay in a fatal ingestion. JAMA 1982; 247: 1596-7.
150. Cheung K, Hinds JA Duffy P. Detection of poisoning by plant-origin cardiac glycoside with the Abbott TDx analyzer. Clin Chem 1989; 35(2): 295-7.
151. Blum LM, Rieders F. Oleandrin distribution in a fatality from rectal and oral Nerium oleander extract administration. J Anal Toxicol 1987; 11: 219-21.
152. +-ATPase by oleandrin and oleandrigenin and their detection by digoxin immunoassays. Clin Chem 1996; 42: 1654-8.
153. Clark RF, Selden BS Curry SC. Digoxin-specific Fab fragments in the treatment of oleander toxicity in a canine model. Ann Emerg Med 1991; 20: 1073-7.
154. Shumaik GM, Wu AW Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med 1988; 17: 732-5.
155. Safadi R, Levy I, Amitai Y, et al. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med 1995; 155: 2121-5.
156. Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Circulation 1990; 81: 1744-52.
157. Pierach CA. Digoxin-like toxicity and death from a purported aphrodisiac. JAMA 1996; 275: 988.
158. Rich SA, Libera JM Locke RJ. Treatment of foxglove extract poisoning with digoxin-specific fab fragments. Ann Emerg Med 1993; 22: 1904-7.
159. Berkovitch M, Akilesh MR Gerace R. Acute digoxin overdose in a newborn with renal failure: use of digoxin immune Fab and peritoneal dialysis. Ther Drug Monit 1994; 16: 531-3.
160. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digoitalis toxicity. Clin Pharmacokinet 1995; 28: 483-93.
161. Miller JJ, Straub RW, Valdes R Jr. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180. Ther Drug Monit 1996; 18: 65-72.
162. Rainey PM. Effects of digoxin immune Fab (ovine) on digoxin immunoassays. Am J Clin Pathol 1989; 92: 779-86.
163. George S, Braithwaite RA Hughes EA. Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. Ann Clin Biochem 1994; 31: 380-2.
164. Lemon M, Andrews DJ, Binks AM, et al. Concentrations of free serum digoxin after treatment with antibody fragments. Br Med J 1987; 295: 1520-1.
165. Honda SA, Rios CN, Murakami L, et al. Problems in determining levels of free digoxin in patients treated with digoxin immune FAb. J Clin Lab Analysis 1995; 9: 407-12.
166. Dods HM, Norris RL, Johnson AG, et al. Evaluation and comparison of the TDxII, Stratus, and Opus digoxin assays. Ther Drug Monit 1995; 17: 68-74.
167. Asano T, Spector S. Identification of inosine and hypoxanthine as endogenous ligands for the brain benzodiazepine-binding sites. Proc Natl Acad Sci USA 1979; 79: 977-81.
168. Gintzler AR, Levy A Spector S. Antibodies as means of characterizing biologically active substrates: presence of a non-peptide morphine-like compound in the central nervous system. Proc Natl Acad Sci USA 1976; 73: 2132-6.
169. Gruber KA. Endogenous druglike substances: implication and approaches to their study. Perspec Biol Med 1982; 26: 51-61.
170. Szent-Gyorgy A. Chemical physiology of contraction in body and heart muscle. New York: Academic Press, 1953.
171. Ryung-Soon K, LaBella FS. Endogenous ligands and modulators of the digitalis receptor: some candidates. Pharm Ther 1981; 14: 391-409.
172. Shimoni Y, Gotsman M, Deutsch J, et al. Endogenous ouabain-like compound increases heart muscle contractility. Nature (London) 1984; 307: 369-71.
173. Laredo J, Hamilton BP Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994; 135: 794-97.
174. Halpert J, Schaefer R, Galves L, et al. Ouabain-like activity in humai cerebrospinal fluid. Proc Natl Acad Sci USA 1983; 80: 6101-4.
175. Janssens SP, Kachoris C Parker WL. Hypothalamic Na+, K(+)-ATPase inhibitor constricts pulmonary arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22(Abstr): S42-6.
176. Tymiak AA, Norman JA, Bolgar M, et al. Physiochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993; 90: 8189-93.
177. Anner BM, Lacotte D, Anner PM, et al. Interaction of hypothalamic Na,K-ATPase inhibitor with isoated human peripheral blood mononuclear cells. Biosci Rep 1994; 14: 231-42.
178. Qazzaz HMAM, Valdes R Jr. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues. Arch Biochem Biophys 1996; 328: 193-200.
179. Besch HR, Hufferd S, Lake M, et al. False elevation of apparent digoxin levels in plasma of premature infants. Clin Chem 1976; 22: 1168.
180. Shaikh IM, Lau BWE, Siegfried A, et al. Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J Biol Chem 1991; 266: 13672-8.
181. Yun WS, Ho CS, Panesar NS, et al. The contribution of steroids to digoxin-like immunoreactivity in cord blood. Ann Clin Biochem 1992; 29: 337-42.
182. Shilo L, Dolev S, Shapiro MS, et al. Endogenous digoxin-like material is of adrenal origin. Isr J Med Sci 1987; 23: 294-5.
183. Di Grande A, Boura ALA, Read MA, et al. Release of substance from human placenta having digoxin-like immunoreactivity. Clin Exp Pharmacol Physiol 1993; 20: 603-7.
184. Wauquire I, Pernollet MG Delva P. High sodium diet and circulating digitalis-like compound in the rat. J Hypertens 1986; 4: 463-9.
185. Graves SW, Lincoln K, Cook SL, et al. Digoxin-like factor and digoxin-like immunoreactive factor in diabetic women with preeclampsia, transient hypertension of pregnancy, and normotensive pregnancy. Am J Hypertension 1995; 8: 5-11.
186. Ahmad S, Kenny M Scribner BH. Hypertension and a digoxin-like substance in plasma of dialysis patients: possible marker for a natriuretic hormone. Clin Physiol Biochem 1986; 210: 210-6.
187. Pickering JW. Observations on the physiology of emberyonic heart. J Physiol 1893; 14: 383-466.
188. Friedman M, Bine R. Employment of embryonic duck heart for the detection of minute amounts of a digitalis glycoside (Lanatoside C). Proc Soc Exp Biol Med 1947; 64: 162-5.
189. Burnett GH, Conklin RL. The enzymatic assay of plasma digoxin. J Lab Clin Med 1971; 78: 779-784.
190. Straub RH, Elbracht R, Kramer BK, et al. Influence of digoxin-like immunoreactive factor on late complications of patients with diabetes mellitus. Eur J Clin Invest 1994; 24: 482-7.
191. Shrivastav P, Gill DS, D'Souza V, et al. Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy. Clin Chem 1988; 34: 977-80.
192. Logoglu G, Erdogan S, Ozgunene FT, et al. Endogenous digoxin-immunoreactivc substance in normal and preeclamptic pregnancies. Int J Gynecol Obstet 1993; 43: 137-43.
193. Yapar EG, Ayhan A. The influence of tocolytic therapy on serum digoxin-like immunoreactive substance concentration. Gynecol Obstet Invest 1994; 37: 10-13.
194. Valdes R Jr, Graves SW, Knight AB, et al. Endogenous digoxin immunoreactivity is elevated in hypertensive pregnancy. Prog Clin Biol Res 1985; 192: 229-232.
195. Shi YS, Liu JH Yu XZ. Observations on serum digoxin-like immunoreactive substances in patients with cor-pulmonale. Chin J Med 1993; 32: 229-31.